Lantern Pharma to Host & Participate in Two Public Webinars During October
Lantern Pharma (NASDAQ: LTRN), an AI-focused oncology drug development company, announced two public webinars in October. The first, on October 28th, features CEO Panna Sharma discussing AI's role in developing therapies for brain and childhood cancers. The second, on October 30th, hosts Actuate Therapeutics' COO Andrew Mazar, highlighting how Lantern's AI platform accelerated the development of Actuate's drug candidate, Elragllusib.
The webinars will showcase RADR®, Lantern's AI platform, and its impact on advancing their portfolio and collaborators' work. Lantern will detail how big data and AI are leveraged to develop LP-184 and LP-284, currently in Phase 1 trials. The company will also discuss their blood-brain-barrier penetrability algorithm, important for LP-184's development in CNS cancer indications, including glioblastoma.
Lantern Pharma has received four Rare Pediatric Disease Designations and the FDA's Fast Track Designation for glioblastoma, underlining their progress in addressing critical unmet needs in oncology.
Lantern Pharma (NASDAQ: LTRN), una compagnia di sviluppo di farmaci oncologici focalizzata sull'IA, ha annunciato due webinar pubblici per ottobre. Il primo, il 28 ottobre, vedrà il CEO Panna Sharma discutere del ruolo dell'IA nello sviluppo di terapie per i tumori cerebrali e pediatrici. Il secondo, il 30 ottobre, ospiterà il COO di Actuate Therapeutics, Andrew Mazar, evidenziando come la piattaforma di IA di Lantern abbia accelerato lo sviluppo del candidato farmaco di Actuate, Elragllusib.
I webinar presenteranno RADR®, la piattaforma di IA di Lantern, e il suo impatto nel far progredire il loro portafoglio e il lavoro dei collaboratori. Lantern dettagliarà come vengono sfruttati i big data e l'IA per sviluppare LP-184 e LP-284, attualmente in fase 1 di sperimentazione. L'azienda discuterà anche del loro algoritmo di penetrazione della barriera emato-encefalica, importante per lo sviluppo di LP-184 nelle indicazioni per il cancro del sistema nervoso centrale, inclusa la glioblastoma.
Lantern Pharma ha ricevuto quattro designazioni per malattie pediatriche rare e la designazione Fast Track della FDA per la glioblastoma, sottolineando i loro progressi nell'affrontare bisogni critici non soddisfatti in oncologia.
Lantern Pharma (NASDAQ: LTRN), una empresa de desarrollo de fármacos oncológicos centrada en IA, anunció dos seminarios web públicos en octubre. El primero, el 28 de octubre, contará con el CEO Panna Sharma discutiendo el papel de la IA en el desarrollo de terapias para el cáncer cerebral y pediátrico. El segundo, el 30 de octubre, tendrá como invitado al COO de Actuate Therapeutics, Andrew Mazar, destacando cómo la plataforma de IA de Lantern ha acelerado el desarrollo del candidato a fármaco de Actuate, Elragllusib.
Los seminarios web mostrarán RADR®, la plataforma de IA de Lantern, y su impacto en el avance de su portafolio y el trabajo de sus colaboradores. Lantern detallará cómo se aprovechan los grandes datos y la IA para desarrollar LP-184 y LP-284, que actualmente están en ensayos de fase 1. La empresa también discutirá su algoritmo de penetrabilidad de la barrera hematoencefálica, importante para el desarrollo de LP-184 en indicaciones de cáncer del SNC, incluido el glioblastoma.
Lantern Pharma ha recibido cuatro designaciones para enfermedades pediátricas raras y la designación Fast Track de la FDA para el glioblastoma, subrayando su progreso en la atención de necesidades críticas no satisfechas en oncología.
랜턴 파마(Lantern Pharma) (NASDAQ: LTRN)는 AI 중심의 항암제 개발 회사로 10월에 두 번의 공개 웨비나를 발표했습니다. 첫 번째 웨비나는 10월 28일에 열리며, CEO인 파나 샤르마가 뇌와 소아암 치료 개발에 있어 AI의 역할에 대해 논의합니다. 두 번째 웨비나는 10월 30일에 진행되며, Actuate Therapeutics의 COO인 앤드류 마자르가 랜턴의 AI 플랫폼이 Actuate의 약물 후보인 Elragllusib 개발을 어떻게 가속화했는지 강조합니다.
웨비나는 RADR®, 랜턴의 AI 플랫폼과 포트폴리오 및 협력자들의 작업을 발전시키는 데 미치는 영향을 보여줍니다. 랜턴은 LP-184 및 LP-284 개발에 있어 대량의 데이터와 AI가 어떻게 활용되는지를 자세히 설명할 예정입니다. 또, LP-184의 중추 신경계 암 적응증, 특히 교모세포종 개발에 중요한 혈뇌장벽 침투 알고리즘에 대해서도 논의할 것입니다.
랜턴 파마는 네 개의 희귀 소아 질병 지정과 향후 치료법 개발을 위한 FDA의 패스트 트랙 지정을 수여받아, 항암 치료에서의 중요한 unmet needs를 해결하기 위한 진전을 강조하고 있습니다.
Lantern Pharma (NASDAQ: LTRN), une société axée sur le développement de médicaments en oncologie utilisant l'IA, a annoncé deux webinaires publics en octobre. Le premier, le 28 octobre, mettra en vedette le PDG Panna Sharma discutant du rôle de l'IA dans le développement de thérapies pour les cancers du cerveau et pédiatriques. Le second, le 30 octobre, accueillera le COO d'Actuate Therapeutics, Andrew Mazar, mettant en avant comment la plateforme d'IA de Lantern a accéléré le développement du candidat médicament d'Actuate, Elragllusib.
Les webinaires mettront en lumière RADR®, la plateforme d'IA de Lantern, et son impact sur l'avancement de leur portefeuille et le travail de leurs collaborateurs. Lantern détaillera comment les grandes données et l'IA sont exploitées pour développer LP-184 et LP-284, actuellement en phase 1 d'essais cliniques. L'entreprise discutera également de leur algorithme de pénétration de la barrière hémato-encéphalique, important pour le développement de LP-184 dans les indications de cancer du SNC, y compris le glioblastome.
Lantern Pharma a reçu quatre désignations pour maladies pédiatriques rares et la désignation Fast Track de la FDA pour le glioblastome, soulignant leurs progrès dans la satisfaction des besoins critiques non comblés en oncologie.
Lantern Pharma (NASDAQ: LTRN), ein auf KI fokussiertes Unternehmen zur Entwicklung von Onkologie-Medikamenten, hat zwei öffentliche Webinare im Oktober angekündigt. Das erste Webinar am 28. Oktober wird von CEO Panna Sharma moderiert, der über die Rolle von KI bei der Entwicklung von Therapien für Gehirn- und Kinderkrebs spricht. Das zweite Webinar am 30. Oktober wird den COO von Actuate Therapeutics, Andrew Mazar, präsentieren, der hervorhebt, wie die KI-Plattform von Lantern die Entwicklung des Arzneimittelkandidaten Elragllusib von Actuate beschleunigt hat.
Die Webinare werden RADR®, die KI-Plattform von Lantern, und deren Einfluss auf die Weiterentwicklung ihres Portfolios und der Arbeiten ihrer Partner präsentieren. Lantern wird erläutern, wie Big Data und KI eingesetzt werden, um LP-184 und LP-284 zu entwickeln, die sich derzeit in der Phase 1 der klinischen Prüfungen befinden. Das Unternehmen wird auch seinen Algorithmus zur Durchdringung der Blut-Hirn-Schranke diskutieren, der für die Entwicklung von LP-184 in Indikationen für Erkrankungen des ZNS, einschließlich Glioblastom, von großer Bedeutung ist.
Lantern Pharma hat vier Auszeichnungen für seltene pädiatrische Krankheiten sowie die Fast Track-Deklaration der FDA für Glioblastom erhalten, was den Fortschritt bei der Behebung kritischer unerfüllter Anforderungen in der Onkologie unterstreicht.
- None.
- None.
- Both webinars will highlight how RADR®, Lantern’s AI platform, has been used to advance their portfolio and the portfolio of their collaborators.
- On October 28th, Lantern’s CEO Panna Sharma will participate in Tribe Public’s webinar event “Leveraging Artificial Intelligence to Develop Therapies for Brain and Childhood Cancers”.
- On October 30th, Lantern will host “Webinar Wednesday” featuring Andrew Mazar, Ph.D., COO of Actuate Therapeutics, to discuss how Lantern’s AI platform aided in the accelerated development and biomarker analytics for Actuate’s drug-candidate, Elragllusib.
- Lantern Pharma has received four Rare Pediatric Disease Designations (RPDD) and was also recently granted the FDA’s Fast Track Designation in glioblastoma.
Lantern expects to discuss in detail how big data and AI are being leveraged to advance the development of multiple indications for drug-candidates LP-184 and LP-284 during the “Leveraging Artificial Intelligence to Develop Therapies for Brain and Childhood Cancers”. Lantern will also discuss how their algorithm for blood-brain-barrier (BBB) penetrability played a critical role in supporting the development of LP-184 across multiple CNS cancer indications, including GBM. This webinar will be hosted by Tribe Public and feature Panna Sharma, Lantern’s President and CEO. Both LP-184 and LP-284 are currently enrolling patients in Phase 1 trials.
Webinar Wednesday will focus on Lantern’s AI-focused collaboration with Actuate Therapeutics, a clinical-stage biopharmaceutical company that went public in August 2024. Andrew Mazar, Ph.D., Chief Operating Officer of Actuate, and Lantern’s computational biologist Joseph McDermott, Ph.D., will discuss the multi-year research and development collaboration that accelerated the development of Actuate’s lead drug candidate, Elraglusib.
Links to Register for October Webinars
- Tribe Public Webinar on October 28, 2024 – https://bit.ly/3BVgPb5
- Lantern Pharma Webinar Wednesday on October 30, 2024 – https://bit.ly/3YsL2XN
ABOUT TRIBE PUBLIC LLC
Tribe Public LLC is a
ABOUT ACTUATE THERAPEUTICS, INC.
Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug product, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy including EMT, NF-kB-mediated resistance and several DDR pathways. Elraglusib also acts as a mediator of anti-tumor immunity through the inhibition of NF-kB in immune cells and regulates multiple immune checkpoints and immune cell function. For additional information, please visit the Company’s website at http://www.actuatetherapeutics.com.
ABOUT LANTERN PHARMA
Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 100 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately
Our lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. We have also established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of our promising therapies for CNS and brain cancers, many of which have no effective treatment options. Our AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over
Please find more information at:
- Website: www.lanternpharma.com
- LinkedIn: https://www.linkedin.com/company/lanternpharma/
- X: @lanternpharma
Forward-looking Statements:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," “model,” "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that our research and the research of our collaborators may not be successful, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (iv) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (v) the risk that no drug product based on our proprietary RADR® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vi) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 18, 2024. You may access our Annual Report on Form 10-K for the year ended December 31, 2023 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241021057341/en/
Investor Relations
mailto: ir@lanternpharma.com
ph: (972) 277-1136
Source: Lantern Pharma Inc.
FAQ
What webinars is Lantern Pharma (LTRN) hosting in October 2024?
What is the focus of Lantern Pharma's (LTRN) October 28th webinar?
How has Lantern Pharma's (LTRN) AI platform helped Actuate Therapeutics?
What recent designations has Lantern Pharma (LTRN) received for its drug candidates?